Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...
The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...
Medpage Today on MSN3d
Pulled Myeloma Drug Improves Survival in TrialA significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...
6d
Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained ...
Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or ...
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback